Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Braz. j. med. biol. res ; 52(7): e8222, 2019. graf
Article in English | LILACS | ID: biblio-1011591

ABSTRACT

Monoclonal gammopathy of renal significance (MGRS) can present with different morphologic features and lead to kidney failure. The Henoch-Schönlein purpura nephritis (HSPN) that cannot be relieved by treatment with glucocorticoid and immunosuppressive agents suggests the presence of monoclonal gammopathy in adult patients. The present study reports on a single case of HSPN associated with IgA-κMGRS. The patient who suffered from recurrent skin purpura for 6 months and nephrotic syndrome for 2 months was admitted to our hospital. Bone marrow biopsy showed monoclonal gammopathy of undetermined significance. Kidney biopsy indicated a Henoch-Schönlein purpura nephritis (HSPN, ISKDC classified as type III) with positive staining with κ-light chain in the glomeruli and renal tubular epithelial cells. Furthermore, skin biopsy showed leukocytoclastic vasculitis and negative staining for Congo red and light chain. Given both the renal and cutaneous involvement, the patient was considered to have HSPN associated with IgA-κMGRS. The patient experienced an exacerbation in his purpura-like lesions and clinical status after treatment with glucocorticoid and immunosuppressive agents. Consequently, the patient was put on a regimen that included dexamethasone (20 mg on the 1st, 4th, 8th, and 11th days of each month, iv) and bortezomib (2.4 mg on the 1st, 4th, 8th, and 11th days of each month, iv). Eight weeks after treatment, he had complete resolution of his cutaneous purpura and his biochemical parameters improved. The latent presence of MGRS in cases of HSPN should be considered in adult patients. Increased cognizance and correct treatment options could improve patient outcomes.


Subject(s)
Humans , Male , Middle Aged , Paraproteinemias/etiology , IgA Vasculitis/complications , Nephritis/complications , Paraproteinemias/pathology , Paraproteinemias/drug therapy , IgA Vasculitis/pathology , IgA Vasculitis/drug therapy , Glucocorticoids/administration & dosage , Immunosuppressive Agents/administration & dosage , Nephritis/pathology , Nephritis/drug therapy
2.
J. bras. nefrol ; 38(4): 450-454, Oct.-Dec. 2016.
Article in English | LILACS | ID: biblio-829074

ABSTRACT

Abstract Light chain deposition disease (LCDD) is a rare clinical entity characterized by the deposition of light chain immunoglobulins in different tissues and primarily affects the kidneys, followed by the liver and heart. This disease often manifests as nephrotic syndrome with marked proteinuria and rapid deterioration of renal function. More than 50% of cases are secondary to multiple myeloma or other lymphoproliferative diseases, with a well-established treatment aimed at controlling the underlying disease. In rare cases, there is no detection of an associated hematological disease, referred to as idiopathic LCDD. In these cases, there is no evidence-based consensus on the therapeutic approach, and management is based on the clinical experience of reported cases. Here we report a case of idiopathic LCDD treated with bortezomib and dexamethasone with complete hematologic responses, significant reduction of proteinuria, and improved renal function.


Resumo A doença de deposição de cadeia leve (DDCL) é uma entidade clínica rara caracterizada pela deposição de cadeias leves das imunoglobulinas em diferentes tecidos e afeta principalmente os rins, seguido pelo fígado e coração. Manifesta-se frequentemente como síndrome nefrótica com proteinúria marcante e rápida deterioração da função renal. Mais de 50% dos casos são secundários ao mieloma múltiplo ou outras doenças linfoproliferativas, tendo seu tratamento bem estabelecido, voltado para o controle da doença de base. Em casos raros, não há detecção de uma doença hematológica associada, sendo referida como DDCL idiopática. Nestes casos, não há um consenso baseado em evidências sobre a abordagem terapêutica, tendo sua conduta baseada na experiência clínica dos casos relatados. Aqui, nós relatamos um caso de DDCL idiopática tratado com bortezomib e dexametasona atingindo resposta hematológica completa, redução significativa da proteinúria e recuperação da função renal.


Subject(s)
Humans , Male , Middle Aged , Paraproteinemias/drug therapy , Dexamethasone/therapeutic use , Immunoglobulin Light Chains , Bortezomib/therapeutic use , Glucocorticoids/therapeutic use , Antineoplastic Agents/therapeutic use , Remission Induction
4.
Rev. chil. urol ; 74(3): 240-242, 2009. ilus
Article in Spanish | LILACS | ID: lil-551922

ABSTRACT

Son infrecuentes los casos de linfoma renal primario, ya que la afectación renal por un proceso linfoproliferativo es, por lo general, secundaria a una enfermedad sistémica. Presentamos el caso de una paciente mujer de 48 años que acude por dolor lumbar y masa abdominal. Después de realizar estudios (TC), se práctica nefrectomía cuyo resultado anatomopatológico fue de linfoma no-hodking B primario renal. Asimismo el paciente presentaba una gammapatía monoclonal IgM asociada, por lo que precisó tratamiento quimioterápico sistémico. Realizamos una revisión bibliográfica centrándonos en los criterios diagnósticos y terapéuticos actuales.


Reports on primary renal lymphoma are scarce in the urological literature, the most part f them are secondary on a lymphomatous infiltration of the kidneys. We report the case of a 48 year old women with lumbar pain and adominal mass. After radiological studies (CT), we practise nephrectomy with a pathological result of a non-hodking B primary lymphoma. The patient present a IgM monoclonal gammapathy who need complementary treatment with chemotherapy. A literature review on currently recommended diagnostic and treatment practices in presented.


Subject(s)
Humans , Female , Middle Aged , Immunoglobulin M/blood , Lymphoma, Non-Hodgkin/complications , Kidney Neoplasms/complications , Paraproteinemias/complications , Chlorambucil/therapeutic use , Lymphoma, Non-Hodgkin/surgery , Lymphoma, Non-Hodgkin/drug therapy , Nephrectomy , Kidney Neoplasms/surgery , Kidney Neoplasms/drug therapy , Paraproteinemias/drug therapy
5.
The Korean Journal of Laboratory Medicine ; : 282-285, 2008.
Article in Korean | WPRIM | ID: wpr-67873

ABSTRACT

We report a case of multiple myeloma showing marked differences in serum Immunoglobulin G (IgG) levels between serum protein electrophoresis and turbidimetry. A 47-yr old man was admitted to our hospital due to severe back pain and diagnosed as having IgG-kappa type multiple myeloma. Serum protein level was 14.4 g/dL at the time of diagnosis. Serum IgG level was 8.5 g/dL by serum protein electrophoresis, but 11.6 g/dL by turbidimetry. The patient's clinical conditions had improved after receiving VAD (vincristine, adriamycin, dexamethasone) and VTD (vincristine, thalidomide, dexamethasone) chemotherapy and there were no differences in IgG levels between electrophoresis and turbidimetry when serum IgG levels were less than 3.0 g/dL. According to this, we considered that both protein electrophoresis and turbidimetry should be needed to quantify serum immunoglobulins for diagnosis and follow-up of the patients with monoclonal gammopathy.


Subject(s)
Humans , Male , Middle Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Electrophoresis, Agar Gel , Immunoglobulin G/blood , Immunoglobulin kappa-Chains/blood , Multiple Myeloma/diagnosis , Nephelometry and Turbidimetry , Paraproteinemias/drug therapy , Time Factors
6.
Rev. dent. Chile ; 85(2): 87-90, ago. 1994. tab
Article in Spanish | LILACS | ID: lil-144089

ABSTRACT

The aim of the present clinical investigation was to evaluate the effect of tranexamic acid in the treatment of discrasies patients. In the study we observed that antifibrinolytic therapy with tranexamic acid used with ystemic therapy significantly reduces the incidence of postoperative bleeding


Subject(s)
Humans , Child , Adolescent , Adult , Tranexamic Acid/therapeutic use , Paraproteinemias/drug therapy , Tranexamic Acid/administration & dosage , Tranexamic Acid/pharmacokinetics , Fibrinolysis/physiology , Thrombolytic Therapy/methods , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL